NEW YORK (GenomeWeb News – Sequenom today reported preliminary full-year revenue of $162 million, an increase of 81 percent over the prior year but shy of consensus analyst estimates of $164.4 million.
Alongside its preliminary financial results, the company said that it is expanding its noninvasive prenatal testing menu by developing a "low cost test on an alternative platform" that it plans to launch by the end of the year. Sequenom's MaterniT21 Plus prenatal trisomy test currently runs on the Illumina sequencing platform.